Broadly neutralizing antiviral antibodies

Annual Review of Immunology

Volumn 31, Issue , 2013, Pages 705-742

  Corti, Davide ^a,b   Lanzavecchia, Antonio ^a,c  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^b Humabs BioMed SA ^*  (Switzerland)

^c ETH ZURICH   (Switzerland)

Author keywords

Dengue; HIV 1; Influenza; Protection; Vaccines; Variability

Indexed keywords

CD16 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DNA POLYMERASE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; MONOCLONAL ANTIBODY 10 1074; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 3BC176; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY C05; MONOCLONAL ANTIBODY CH65; MONOCLONAL ANTIBODY CR6261; MONOCLONAL ANTIBODY CR8020; MONOCLONAL ANTIBODY CR9114; MONOCLONAL ANTIBODY F10; MONOCLONAL ANTIBODY FI6; MONOCLONAL ANTIBODY PG16; MONOCLONAL ANTIBODY PG9; MONOCLONAL ANTIBODY PGT128; MONOCLONAL ANTIBODY VHI 69; MONOCLONAL ANTIBODY VRC01; NEUTRALIZING ANTIBODY; PROTEIN M2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS RNA;

ADAPTIVE IMMUNITY; ADENO ASSOCIATED VIRUS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; BINDING SITE; CD4+ T LYMPHOCYTE; DENGUE VIRUS; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENCEPHALITIS VIRUS; GENETIC VARIABILITY; HEAVY CHAIN; HEMAGGLUTINATION; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN METAPNEUMOVIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LIGHT CHAIN; MEMORY CELL; NATURAL KILLER CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; VIRUS ENTRY; VIRUS REPLICATION; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; INFLUENZA, HUMAN; MOLECULAR TARGETED THERAPY; NEUTRALIZATION TESTS;

EID: 84875551472     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032712-095916     Document Type: Review

References (219)

1. Zinkernagel RM. 2001. Maternal antibodies, childhood infections, and autoimmune diseases. N. Engl. J. Med. 345(18):1331-35
2. Burton D, Desrosiers R, Doms R, Koff W, Kwong P, et al. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5(3):233-36
3. Parren PW, Burton DR. 2001. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77:195-262
4. Klasse PJ, Sattentau QJ. 2002. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83(9):2091-108
5. Mallery DL, McEwanWA, Bidgood SR, Towers GJ, Johnson CM, James LC. 2010. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl. Acad. Sci. USA 107(46):19985-90
6. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, et al. 2004. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J. Infect. Dis. 189(2):286-91
7. Jacobson J, Saag M, Thompson M, Fischl M, Liporace R, et al. 2008. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J. Infect. Dis. 198(9):1345-52
8. Rizzuto CD, Sodroski JG. 1997. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J. Virol. 71(6):4847-51
9. Arthur LO, Bess JW, Sowder RC, Benveniste RE, Mann DL, et al. 1992. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258(5090):1935-38
10. Grandea AG, Olsen OA, Cox TC, Renshaw M, Hammond PW, et al. 2010. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc. Natl. Acad. Sci. USA 107(28):12658-63
11. Beerli RR, BauerM, Schmitz N, Buser RB, GwerderM, et al. 2009. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol. J. 6(1):224
12. Pinna D, CortiD, JarrossayD, Sallusto F, Lanzavecchia A. 2009. Clonal dissection of the humanmemory B-cell repertoire following infection and vaccination. Eur. J. Immunol. 39(5):1260-70
13. Duffy S, Shackelton LA, Holmes EC. 2008. Rates of evolutionary change in viruses: patterns and determinants. Nat. Rev. Genet. 9(4):267-76
14. Smith D, Lapedes A, de Jong J, Brockman-Schneider CJ, Rimmelzwaan G, et al. 2004. Mapping the antigenic and genetic evolution of influenza virus. Science 305(5682):371-76
15. Smith TJ. 2011. Structural studies on antibody recognition and neutralization of viruses. Curr. Opin. Virol. 1(2):150-56
16. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Biochem. 24:739-69
17. BuonaguroL, Tornesello ML, Buonaguro FM. 2007.Humanimmunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J. Virol. 81(19):10209-19
18. Taylor BS, Hammer SM. 2008. The challenge ofHIV-1 subtype diversity. N. Engl. J.Med. 359(18):1965-66
19. Binley JM, Ban Y-EA, Crooks ET, Eggink D, Osawa K, et al. 2010. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization. J. Virol. 84(11):5637-55
20. Wu X, Zhou T, O'Dell S, Wyatt RT, Kwong PD, Mascola JR. 2009. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 83(21):10892-907
21. Quakkelaar ED, Bunnik EM, van Alphen FPJ, Boeser-Nunnink BDM, van Nuenen AC, Schuitemaker H. 2007. Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. Virology 363(2):447-53
22. Seaman MS, Janes H, HawkinsN, Grandpre LE, Devoy C, et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84(3):1439-52
23. Zolla-Pazner S. 2004. Identifying epitopes ofHIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4(3):199-210
24. Burton DR, Barbas CF, Persson MA, Koenig S, Chanock RM, Lerner RA. 1991. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 88(22):10134-37
25. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266(5187):1024-27
26. Kunert R, Ruker F, Katinger H. 1998. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res. Hum. Retrovir. 14(13):1115-28
27. Calarese D, Scanlan C, Zwick M, Deechongkit S, Mimura Y, et al. 2003. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300(5628):2065-71
28. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, et al. 1994. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retrovir. 10(4):359-69
29. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75(22):10892-905
30. Zhu Z, Qin HR, Chen W, Zhao Q, Shen X, et al. 2011. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J. Virol. 85(21):11401-8
31. Zwick M, Jensen R, Church S, Wang M, Stiegler G, et al. 2005. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 79(2):1252-61
32. Binley J, Wrin T, Korber B, Zwick M, Wang M, et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78(23):13232-52
33. Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. 2007. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364(2):441-53
34. Conley A, Gorny M, Kessler J, Brockman-Schneider CJ, Ossorio-Castro M, et al. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68(11):6994-7000
35. Gorny M, Williams C, Volsky B, Revesz K, Wang X, et al. 2006. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J. Virol. 80(14):6865-72
36. Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, et al. 2002. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76(18):9035-45
37. Labrijn A, Poignard P, Raja A, Zwick M, Delgado K, et al. 2003. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J. Virol. 77(19):10557-65
38. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a highthroughput neutralization assay together with an analytical selection algorithm. J. Virol. 83(14):7337-48
39. Walker LM, Phogat SK, Chan-Hui P-Y, WagnerD, Phung P, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950):285-89
40. GornyM, Stamatatos L, Volsky B, Revesz K, Williams C, et al. 2005. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79(8):5232-37
41. Wu X, Changela A, O'Dell S, Schmidt SD, PanceraM, et al. 2011. Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J. Virol. 85(9):4578-85
42. McLellan JS, Pancera M, Carrico C, Gorman J, Julien J-P, et al. 2011. Structure ofHIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480(7377):336-43
43. Doria-Rose NA, Georgiev I, O'Dell S, Chuang G-Y, Staupe RP, et al. 2012. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J. Virol. 86(15):8319-23
44. Bonsignori M, Hwang K-K, Chen X, Tsao C-Y, Morris L, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85(19):9998-10009
45. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477(7365):466-70
46. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang P-S, et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334(6059):1097-103
47. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, et al. 2012. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 109(47):E3268-77
48. Huang J, Ofek G, Laub L, LouderMK, Doria-Rose NA, et al. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491(7424):406-12
49. Haynes B, Fleming J, St Clair E, Katinger H, Stiegler G, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308(5730):1906-8
50. Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 5(1):e8805
51. Pietzsch J, Scheid JF, Mouquet H, Klein F, Seaman MS, et al. 2010. Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J. Exp.Med. 207(9):1995-2002
52. SabinC, Corti D, BuzonV, SeamanMS, Lutje Hulsik D, et al. 2010. Crystal structure and size-dependent neutralization properties ofHK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog. 6(11):e1001195
53. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, et al. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13(9):1032-34
54. Wu X, Yang Z-Y, Li Y, Hogerkorp C-M, SchiefWR, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329(5993):856-61
55. Zhou T, Georgiev I, Wu X, Yang Z-Y, Dai K, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329(5993):811-17
56. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333(6049):1593-602
57. Scheid JF, MouquetH, FeldhahnN, SeamanMS, Velinzon K, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238):636-40
58. Scheid JF, MouquetH, UeberheideB, DiskinR, Klein F, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333(6049):1633-37
59. Diskin R, Scheid JF, Marcovecchio PM, West AP, Klein F, et al. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334(6060):1289-93
60. Falkowska E, Ramos A, Feng Y, Zhou T, Moquin S, et al. 2012. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86(8):4394-403
61. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, et al. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326(5956):1123-27
62. McCoy LE, Quigley AF, Strokappe NM, Bulmer-Thomas B, SeamanMS, et al. 2012. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 209(6):1091-103
63. Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, et al. 2012. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 209(8):1469-79
64. Tieleman DP, Berendsen HJ. 1998. A molecular dynamics study of the pores formed by Escherichia coli OmpF porin in a fully hydrated palmitoyloleoylphosphatidylcholine bilayer. Biophys. J. 74(6):2786-801
65. Mascola J, Lewis M, Stiegler G, Harris D, VanCott T, et al. 1999. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73(5):4009-18
66. Mascola J, Stiegler G, VanCott T, Katinger H, Carpenter C, et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6(2):207-10
67. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75(17):8340-47
68. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, et al. 2000. Human neutralizingmonoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6(2):200-6
69. Ferrantelli F, Rasmussen RA, BuckleyKA, Li P-L, Wang T, et al. 2004. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J. Infect. Dis. 189(12):2167-73
70. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, et al. 2001. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J. Virol. 75(16):7470-80
71. Barin F, Jourdain G, Ngo-Giang-Huong N, Weerawatgoompa S, Karnchanamayul W, et al. 2006. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1. J. Infect. Dis. 193(11):1504-11
72. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, et al. 2010. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBaL. J. Virol. 84(3):1302-13
73. Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, et al. 2011. An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS ONE 6(3):e18207
74. Hessell A, Rakasz E, Poignard P, Hangartner L, Landucci G, et al. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5(5):e1000433
75. Mozdzanowska K, FurchnerM, Washko G, Mozdzanowski J, Gerhard W. 1997. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J. Virol. 71(6):4347-55
76. Hessell AJ, Hangartner L, Hunter M, Havenith CEG, Beurskens FJ, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158):101-4
77. Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, et al. 2012. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86(11):6189-96
78. Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, et al. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. USA 108(27):11181-86
79. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, et al. 2009. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15(8):901-6
80. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. 2012. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481(7379):81-84
81. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, et al. 2007. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J. Virol. 81(16):8793-808
82. Trkola A, Kuster H, Rusert P, Joos B, FischerM, et al. 2005. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11(6):615-22
83. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, et al. 2012. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492(7427):118-22
84. van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, et al. 2010. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness inHIV-1-infected progressors and long-term nonprogressors. J. Virol. 84(7):3576-85
85. Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BDM, Grijsen ML, et al. 2011. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J. Virol. 85(14):7236-45
86. + T cell decline and high viral load during acute infection. J. Virol. 85(10):4828-40
87. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7(1):e1001251
88. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, et al. 2009. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390(3):404-9
89. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, et al. 2010. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467(7315):591-95
90. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30(5):423-33
91. Choe H, Li W, Wright PL, Vasilieva N, VenturiM, et al. 2003. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114(2):161-70
92. Farzan M, Mirzabekov T, Kolchinsky P, Wyatt R, Cayabyab M, et al. 1999. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 96(5):667-76
93. Skehel JJ, Wiley DC. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69:531-69
94. NobusawaE, AoyamaT, KatoH, SuzukiY, TatenoY, NakajimaK. 1991. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 182(2):475-85
95. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. 1992. Evolution and ecology of influenza A viruses. Microbiol. Rev. 56(1):152-79
96. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, et al. 2008. The global circulation of seasonal influenza A (H3N2) viruses. Science 320(5874):340-46
97. Hay AJ, Gregory V, Douglas AR, Lin YP. 2001. The evolution of human influenza viruses. Philos. Trans. R. Soc. Lond. B 356(1416):1861-70
98. Both GW, Sleigh MJ, Cox NJ, Kendal AP. 1983. Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites. J. Virol. 48(1):52-60
99. Wiley DC, Wilson IA, Skehel JJ. 1981. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289(5796):373-78
100. Caton A, Brockman-Schneider CJ, Yewdell J, GerhardW. 1982. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31(2):417-27
101. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67(5):2552-58
102. Okuno Y, Matsumoto K, Isegawa Y, Ueda S. 1994. Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 68(1):517-20
103. + memory B cells. PLoS ONE 3(12):e3942
104. Sui J, HwangWC, Perez S, WeiG, AirdD, et al. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16(3):265-73
105. Ekiert DC, Bhabha G, Elsliger M-A, Friesen RHE, Jongeneelen M, et al. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924):246-51
106. Corti D, Suguitan AL, Pinna D, Silacci C, Fernandez-Rodriguez BM, et al. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Investig. 120(5):1663-73
107. Wrammert J, KoutsonanosD, LiG-M, Edupuganti S, Sui J, et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp.Med. 208(1):181-93
108. Ekiert DC, Friesen RHE, Bhabha G, Kwaks T, Jongeneelen M, et al. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333(6044):843-50
109. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333(6044):850-56
110. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, et al. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337(6100):1343-48
111. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, et al. 2009. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 5(3):e1000350
112. Whittle JRR, Zhang R, Khurana S, King LR, Manischewitz J, et al. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 108(34):14216-21
113. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, et al. 2012. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489(7417):526-32
114. Calder LJ, Wasilewski S, Berriman JA, Rosenthal PB. 2010. Structural organization of a filamentous influenza A virus. Proc. Natl. Acad. Sci. USA 107(23):10685-90
115. Temperton NJ, Hoschler K, Major D, Nicolson C, Manvell R, et al. 2007. A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir. Viruses 1(3):105-12
116. Hai R, Krammer F, Tan GS, Pica N, Eggink D, et al. 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86(10):5774-81
117. Palese P, Wang TT. 2011. Why do influenza virus subtypes die out-A hypothesis. mBio 2(5):e00150-11
118. Pica N, Hai R, Krammer F, Wang TT, Maamary J, et al. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. USA 109(7):2573-78
119. Murphy BR, Kasel JA, Chanock RM. 1972. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N. Engl. J. Med. 286(25):1329-32
120. Sandbulte MR, Jimenez GS, Boon ACM, Smith LR, Treanor JJ, Webby RJ. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4(2):e59
121. Gioia C, Castilletti C, Tempestilli M, Piacentini P, Brockman-Schneider CJ, et al. 2008. Crosssubtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg. Infect. Dis. 14(1):121-28
122. Marcelin G, Dubois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ. 2011. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS ONE 6(10):e26335
123. Mozdzanowska K, Feng J, Eid M, ZharikovaD, Gerhard W. 2006. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 352(2):418-26
124. Feng JQ, Mozdzanowska K, Gerhard W. 2002. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J. Virol. 76(3):1369-78
125. VerbonitzMW, Ennis FA, Hicks JT, Albrecht P. 1978. Hemagglutinin-specific complement-dependent cytolytic antibody response to influenza infection. J. Exp. Med. 147(1):265-70
126. Terajima M, Cruz J, Co MDT, Lee J-H, Kaur K, et al. 2011. Complement-dependent lysis of influenza A virus-infected cells by broadly cross-reactive human monoclonal antibodies. J. Virol. 85(24):13463-67
127. Nimmerjahn F, Ravetch JV. 2008. Fcγreceptors as regulators of immune responses. Nat. Rev. Immunol. 8(1):34-47
128. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, et al. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186(2):1022-31
129. Moore GL, Chen H, Karki S, Lazar GA. 2010. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2(2):181-89
130. Bruhns P. 2012. Properties ofmouse and human IgG receptors and their contribution to disease models. Blood 119(24):5640-49
131. Smith P, Dilillo DJ, Bournazos S, Li F, Ravetch JV. 2012. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109(16):6181-86
132. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. 2006. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann. Intern. Med. 145(8):599-609
133. Hung IF, To KK, Lee C-K, Lee K-L, Chan K, et al. 2011. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52(4):447-56
134. Zhou B, ZhongN, Guan Y. 2007. Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 357(14):1450-51
135. Sasso EH, Johnson T, Kipps TJ. 1996. Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J. Clin. Investig. 97(9):2074-80
136. Lingwood D, McTammey PM, Yassine HM, Whittle J, Guo X, et al. 2012. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489(7417):566-70
137. Zhang Y, Zhang W, Ogata S, Clements D, Strauss JH, et al. 2004. Conformational changes of the flavivirus E glycoprotein. Structure 12(9):1607-18
138. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2-A resolution. Nature 375(6529):291-98
139. Modis Y, Ogata S, Clements D, Harrison SC. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA 100(12):6986-91
140. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437(7059):764-69
141. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, et al. 2002. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis. 8(12):1474-79
142. Halstead SB. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60:421-67
143. Simmons CP, Farrar JJ, Nguyen VVC, Wills B. 2012. Dengue. N. Engl. J. Med. 366(15):1423-32
144. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. 2007. The stoichiometry of antibodymediated neutralization and enhancement ofWest Nile virus infection. Cell Host Microbe 1(2):135-45
145. DejnirattisaiW, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328(5979):745-48
146. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. 2010. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8(3):271-83
147. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11(5):522-30
148. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, et al. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6(2):e1000790
149. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. 1998. Binding of hepatitis C virus to CD81. Science 282(5390):938-41
150. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, et al. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137):801-5
151. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, et al. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457(7231):882-86
152. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, et al. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21(19):5017-25
153. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309(5734):623-26
154. Broering TJ, Garrity KA, Boatright NK, Sloan SE, Sandor F, et al. 2009. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 83(23):12473-82
155. Sabo MC, Luca VC, Prentoe J, Hopcraft SE, Blight KJ, et al. 2011. Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J. Virol. 85(14):7005-19
156. Schofield DJ, Bartosch B, Shimizu YK, Allander T, Alter HJ, et al. 2005. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42(5):1055-62
157. Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, et al. 2007. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. USA 104(41):16269-74
158. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, et al. 2008. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14(1):25-27
159. Giang E, DornerM, Prentoe JC, Dreux M, EvansMJ, et al. 2012. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc. Natl. Acad. Sci. USA 109(16):6205-10
160. Keck Z-Y, Xia J, Wang Y, Wang W, Krey T, et al. 2012. Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV e2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog. 8(4):e1002653
161. Rychlowska M, Owsianka AM, Foung SKH, Dubuisson J, Bienkowska-Szewczyk K, Patel AH. 2011. Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships. J. Gen. Virol. 92(10):2249-61
162. Meunier J, Russell R, Goossens V, Priem S, Walter H, et al. 2008. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the E1 glycoprotein of hepatitis C virus. J. Virol. 82(2):966-73
163. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, et al. 2011. A genetically humanized mouse model for hepatitis C virus infection. Nature 474(7350):208-11
164. Gal-Tanamy M, Keck Z-Y, Yi M, McKeating JA, Patel AH, et al. 2008. In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc. Natl. Acad. Sci. USA 105(49):19450-55
165. Zhang P, Wu C, Mihalik K, Virata-Theimer M, Yu M, et al. 2007. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl. Acad. Sci. USA 104(20):8449-54
166. Meyer K, Ait-Goughoulte M, Keck Z-Y, Foung S, Ray R. 2008. Antibody-dependent enhancement of hepatitis C virus infection. J. Virol. 82(5):2140-49
167. Sette A, Rappuoli R. 2010. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33(4):530-41
168. Burton D. 2002. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2(9):706-13
169. Dormitzer PR, Ulmer JB, Rappuoli R. 2008. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26(12):659-67
170. Zielinski CE, Corti D, Mele F, Pinto D, Lanzavecchia A, Sallusto F. 2011. Dissecting the human immunological memory for pathogens. Immunol. Rev. 240(1):40-51
171. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, et al. 2010. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 84(2):1005-13
172. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, et al. 2004. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 78(18):10023-33
173. Ryckman BJ, Rainish BL, ChaseMC, Borton JA, Nelson JA, et al. 2008. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J. Virol. 82(1):60-70
174. Wang D, Shenk T. 2005. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 79(16):10330-38
175. Baldanti F, Paolucci S, Campanini G, Sarasini A, Percivalle E, et al. 2006. Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates. Arch. Virol. 151(6):1225-33
176. Pass RF. 2009. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J. Clin. Virol. 46:S73-76
177. Potzsch S, Spindler N, Wiegers A-K, Fisch T, Rucker P, et al. 2011. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog. 7(8):e1002172
178. Lilleri D, Kabanova A, Lanzavecchia A, Gerna G. 2012. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J. Clin. Immunol. doi:10.1007/s10875-012-9739-3
179. Heyman B. 2000. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu. Rev. Immunol. 18:709-37
180. NgCT, Jaworski JP, Jayaraman P, SuttonWF, Delio P, et al. 2010. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16(10):1117-19
181. Stott EJ. 1994. Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines. Curr. Top. Microbiol. Immunol. 188:221-37
182. FlynnNM, ForthalDN, Harro CD, Judson FN, Mayer KH, ParaMF. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5):654-65
183. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. 2006. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194(12):1661-71
184. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258(5090):1938-41
185. Whitney JB, Ruprecht RM. 2004. Live attenuated HIV vaccines: pitfalls and prospects. Curr. Opin. Infect. Dis. 17(1):17-26
186. Steinbrook R. 2007. One step forward, two steps back-will there ever be an AIDS vaccine? N. Engl. J. Med. 357(26):2653-55
187. Ferrantelli F, Rasmussen RA, Hofmann-Lehmann R, Xu W, McClure HM, Ruprecht RM. 2002. Do not underestimate the power of antibodies-lessons from adoptive transfer of antibodies against HIV. Vaccine 20(Suppl. 4):A61-65
188. Fauci A, Johnston M, Dieffenbach C, Brockman-Schneider CJ, Hammer S, et al. 2008. HIV vaccine research: the way forward. Science 321(5888):530-32
189. Walker B, Brockman-Schneider CJ. 2008. Toward an AIDS vaccine. Science 320(5877):760-64
190. Mascola JR, Montefiori DC. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28(1):413-44
191. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23):2209-20
192. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366(14):1275-86
193. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, et al. 2012. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206(3):431-41
194. Amanna I, Carlson N, Slifka M. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357(19):1903-15
195. Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, et al. 2010. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS ONE 5(4):e10254
196. Wu X, Sambor A, Nason MC, Yang Z-Y, Wu L, et al. 2008. Soluble CD4 broadens neutralization of V3-directedmonoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B andCreference viruses. Virology 380(2):285-95
197. Krashias G, Simon A-K, Wegmann F, KokWL, Ho LP, et al. 2010. Potent adaptive immune responses induced against HIV-1 gp140 and influenza virusHAby a polyanionic carbomer. Vaccine 28(13):2482-89
198. Lai RPJ, SeamanMS, Tonks P, Wegmann F, Seilly DJ, et al. 2012. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. PLoS ONE 7(4):e35083
199. Ofek G, Guenaga FJ, Schief WR, Skinner J, Baker D, et al. 2010. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. USA 107(42):17880-87
200. Guenaga J, Dosenovic P, Ofek G, Baker D, Schief WR, et al. 2011. Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS ONE 6(1):e16074
201. AzoiteiML, Correia BE, Ban Y-EA, Carrico C, KalyuzhniyO, et al. 2011. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold. Science 334(6054):373-76
202. BomselM, Tudor D, Drillet A-S, Alfsen A, Ganor Y, et al. 2011. Immunization withHIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34(2):269-80
203. Carrat F, Flahault A. 2007. Influenza vaccine: the challenge of antigenic drift. Vaccine 25(39-40):6852-62
204. Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, et al. 2012. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr. Infect. Dis. J. 31(7):745-51
205. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12(1):36-44
206. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, et al. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2(15):15ra5
207. Graves PN, Schulman JL, Young JF, Palese P. 1983. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 126(1):106-16
208. Sagawa H, Ohshima A, Kato I, Okuno Y, Isegawa Y. 1996. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J. Gen. Virol. 77(7):1483-87
209. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, et al. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1(1):e00018-10
210. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, et al. 2010. Design of an HA2-based Escherichia coli expressed influenza immunogen that protectsmice from pathogenic challenge. Proc. Natl. Acad. Sci. USA 107(31):13701-6
211. Wang TT, Tan GS, Hai R, Pica N, Petersen E, et al. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 6(2):e1000796
212. Wang TT, Tan GS, Hai R, Pica N, Ngai L, et al. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. USA 107(44):18979-84
213. Schneemann A, Speir JA, Tan GS, Khayat R, Ekiert DC, et al. 2012. A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J. Virol. 86(21):11686-97
214. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10):1157-63
215. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, et al. 2003. Induction of influenza type A virusspecific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21(19-20):2616-26
216. Schmitz N, Beerli RR, Bauer M, Jegerlehner A, Dietmeier K, et al. 2012. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur. J. Immunol. 42(4):863-69
217. Tissot AC, Renhofa R, SchmitzN, Cielens I, Meijerink E, et al. 2010. Versatile virus-like particle carrier for epitope based vaccines. PLoS ONE 5(3):e9809
218. Li G-M, Chiu C, Wrammert J, McCausland M, Andrews SF, et al. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. USA 109(23):9047-52
219. Fazekas de St Groth S, Webster RG. 1966. Disquisitions on original antigenic sin. I. Evidence in man. J. Exp. Med. 124(3):331-45